Dallas Voice (Dallas, Tex.), Vol. 28, No. 21, Ed. 1 Friday, October 7, 2011 Page: 39 of 68
The following text was automatically extracted from the image on this page using optical character recognition software:
viramune xr 400 mg tablets is a prescription medicine for use in combination with other hiv
medicines to treat hiv in adults.
Ask your healthcare provider about the Co-Pay Savings Program for VIRAMUNE XR today.
Taking Viramune® XR"-' (nevirapine) extended-release tablets? if so, you may be eligible for the VIRAMUNE XR Co-Pay Savings Program. The Co-Pay Savings Card
may pay the entire cost of your first VIRAMUNE XR monthly co-pay. Then, it may save you up to $100 off your monthly prescription co-pay for up to a year. It also
provides you access to the Vlife on Therapyprogram—a free educational support program. Talk to your healthcare provider or visit www.viramunexr.com to
learn more about the terms, conditions, and benefits of the card and program.
Terms and Conditions of viramune xr Co-Pay Savings Program.
The VIRAMUNE XR Co-Pay Card is not valid for prescriptions purchased under Medicaid, Medicare, or similar federal, state or other government-funded benefit
programs. Cash paying customers and residents of Massachusetts (and states where prohibited by law) are not eligible for this offer. This program is only
available for individuals 18 years of age or older.
Boehringer tngelheim Pharmaceuticals, inc. reserves the right to change the terms and conditions of this offer at any point
The VIRAMUNE XR Co-Pay Savings Card is issued by The Bancorp Bank pursuant to the license by MasterCard International Incorporated.
The issuers shall not be liable to the users for losses, expenses, claims, or other damages that the user may incur as a result of this card.
VIRAMUNE is a prescription medication indicated for use in combination with other antiretroviral (ARV) agents for the treatment of HIV infection.
VIRAMUNE XR is a prescription medication indicated for use in combination with other ARVs for the treatment of Hiv infection in adults.
IMPORTANT SAFETY INFORMATION
VIRAMUNE and VIRAMUNE XR can cause severe and life-threatening liver and skin reactions that can, in some cases, cause death. These problems can happen at any time
but occur most often during the first 18 weeks of treatment, but can occur later. People who have abnormal liver test results before starting VIRAMUNE treatment and
people with hepatitis B or C also have a greater chance of getting liver problems.Your healthcare provider (HCP) will closely monitor you and test the function of your liver
during the first 18 weeks of therapy. Ask your healthcare provider how to recognize symptoms of liver and skin problems. Do not take VIRAMUNE unless you have been
diagnosed with HIV.
You must stop taking VIRAMUNE or VIRAMUNE XR and call your HCP immediately if you have signs or symptoms of liver or skiri problems. If you stop treatment with VIRAMUNE because you had any
serious liver or skin reactions, you must never take VIRAMUNE again. For some patients, damage to the liver can continue to occur after VIRAMUNE is stopped.
Any patient can experience liver problems with VIRAMUNE or VIRAMUNE XR, but women and patients who have higher CD4+ counts when they begin nevirapine treatment have a greater risk. If
you are a woman with CD4+ greater than 250 cells/mm3, or a man with CD4+ greater than 400 cells/mm3, you should not begin taking VIRAMUNE unless you and your doctor
have decided that the benefit of doing so outweighs the risk. Women, including pregnant women, with CD4+ cell counts greater than 250 cells/mm3 are at the greatest risk
of severe liver problems.
Do not take viramune or viramune xr unless you have been diagnosed with hiv. do not take viramune or viramune xr if your hcp has told you that you have moderate to severe liver disease.
viramune and viramune xr can cause serious side effects, including changes to your immune system (Immune Reconstitution Syndrome) and changes in body fat. The most common side effect
of viramune is rash. These are not all the possible side effects of viramune. For more information, ask your hcp
You should not take St. John's wort or efavirenz if you take viramune or viramune xr. Talk to your hcp about the additional drug to drug interactions associated with viramune and viramune xr.
viramune and viramune xr do not cure hiv or aids, and have not been shown to reduce the risk of passing Hiv to others through sexual contact or blood contamination.
Patients new to nevirapine must start treatment with a lead-in dose of one 200 mg tablet of immediate-release VIRAMUNE once daily for the first 14 days of treatment. Tie 14-day lead-in period is
important because it has been shown to reduce your chances of getting a potentially serious skin rash, if you experience a rash during the first 14 days, immediately contact your HCP and do not
increase your dose to viramune 200 mg twice daily or start viramune xr 400 mg once daily until the rash has resolved, if your rash persists longer than 28 days, stop taking viramune and call
your HCP for an alternative regimen. If you stop taking viramune or viramune xr for longer than seven days, talk to your HCP because you will need to restart the 14-day lead-in dose.
Adult patients already on a regimen of VIRAMUNE 200 mg twice daily can be switched to VIRAMUNE XR 400 mg once daily without the 14-day lead-in period of VIRAMUNE.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Medication Guide, which includes dosing information and additional important risk information,
for VIRAMUNE XR, on the following pages.
Ask your HCP if it's the right option for you. Visit www.viramunexr.com for more information.
10.07.11 ■ dallasvoice 39
Here’s what’s next.
This issue can be searched. Note: Results may vary based on the legibility of text within the document.
Tools / Downloads
Get a copy of this page or view the extracted text.
Citing and Sharing
Basic information for referencing this web page. We also provide extended guidance on usage rights, references, copying or embedding.
Reference the current page of this Newspaper.
Nash, Tammye. Dallas Voice (Dallas, Tex.), Vol. 28, No. 21, Ed. 1 Friday, October 7, 2011, newspaper, October 7, 2011; Dallas, Texas. (digital.library.unt.edu/ark:/67531/metapth239188/m1/39/: accessed March 18, 2018), University of North Texas Libraries, Digital Library, digital.library.unt.edu; crediting UNT Libraries Special Collections.